1,345
Views
2
CrossRef citations to date
0
Altmetric
Review

Respiratory comorbidities in severe asthma: focus on the pediatric age

ORCID Icon, , ORCID Icon, , ORCID Icon &
Pages 1-13 | Received 14 Aug 2022, Accepted 10 Jan 2023, Published online: 17 Jan 2023

References

  • Asher MI, García-Marcos L, Pearce NE, et al. Trends in worldwide asthma prevalence. Eur Respir J. 2020;56(6):2002094.
  • Sestini P, De Sario M, Bugiani M, et al. La prevalenza di asma e allergie nei bambini e adolescenti italiani: i risultati del progetto SIDRIA-2 [Frequency of asthma and allergies in Italian children and adolescents: results from SIDRIA-2]. Epidemiol Prev. 2005;29(2 Suppl):24–31. Italian
  • Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2022 GINA main report. [cited 14 Aug 2022]. Available from: https://ginasthma.org/reports/.
  • Chung KF, Wenzel SE, Brozek JL, et al., International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. .
  • Hiles SA, Gibson PG, Agusti A, et al. Treatable traits that predict health status and treatment response in airway disease. J Allergy Clin Immunol Pract. 2021;9(4):1255–1264.e2.
  • Licari A, Brambilla I, Marseglia A, et al. Difficult vs severe asthma: definition and limits of asthma control in the pediatric population. Front Pediatr. 2018;6:170.
  • Bush A. This child’s asthma appears to be severe: but where actually is the severe problem? Acta Med Acad. 2020;49(2):11–21.
  • Andrenacci B, Ferrante G, Roberto G, et al. Challenges in uncontrolled asthma in pediatrics: important considerations for the clinician. Expert Rev Clin Immunol. 2022;18(8):807–821.
  • Hekking PW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.
  • Fainardi V, Esposito S, Chetta A, et al. Asthma phenotypes and endotypes in childhood. Minerva Med. 2022;113(1):94–105.
  • Polverino E, Goeminne PC, McDonnell MJ, et al. European respiratory society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.
  • Bardin PG, Rangaswamy J, Yo SW. Managing comorbid conditions in severe asthma. Med J Aust. 2018;209:S11–7. .
  • Rogliani P, Sforza M, Calzetta L. The impact of comorbidities on severe asthma. Curr Opin Pulm Med. 2020;26(1):47–55.
  • Su X, Ren Y, Li M, et al. Prevalence of comorbidities in asthma and nonasthma patients: a meta-analysis. Medicine (Baltimore). 2016;95(22):e3459.
  • Porsbjerg C, Menzies-Gow A. Co-morbidities in severe asthma: clinical impact and management. Respirology. 2017;22:651–661.
  • Fasola S, Ferrante G, Cilluffo G, et al. Asthma comorbidities: frequency, risk factors, and associated burden in children and adolescents. Children (Basel). 2022;9(7):1001.
  • Tay TR, Radhakrishna N, Hore-Lacy F, et al. Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. Respirology. 2016;21(8):1384–1390.
  • Kachroo P, Stewart ID, Kelly RS, et al. Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma. Nat Med. 2022;28(4):814–822.
  • Weatherburn CJ, Guthrie B, Mercer SW, et al. Comorbidities in adults with asthma: population-based cross-sectional analysis of 1.4 million adults in Scotland. Clin Exp Allergy. 2017;47(10):1246–1252.
  • Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3.
  • Zicari AM, De Castro G, Leonardi L, et al. Update on rhinitis and rhinosinusitis. Pediatr Allergy Immunol. 2020;31(Suppl 24):32–33.
  • Brożek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol. 2017;140(4):950–958.
  • Settipane RA, Lieberman P. Update on nonallergic rhinitis. Ann Allergy Asthma Immunol. 2001;86(5):494–507.
  • Maselli Del Giudice A, Barbara M, Russo GM, et al. Cell-mediated non-allergic rhinitis in children. Int J Pediatr Otorhinolaryngol. 2012;76(12):1741–1745.
  • Poddighe D, Gelardi M, Licari A, et al. Non-allergic rhinitis in children: epidemiological aspects, pathological features, diagnostic methodology and clinical management. World J Methodol. 2016;6(4):200–213.
  • Licari A, Ciprandi G, Marseglia GL, et al. Asthma in children and adolescents: the ControL’Asma project. Acta Biomed. 2020;91(11–S):e2020002.
  • Tosca MA, Duse M, Marseglia G, et al. The practical clinical relevance of rhinitis classification in children with asthma: outcomes of the “ControL’Asma” study. Ann Allergy Asthma Immunol. 2019;123(5):516–519.
  • Klain A, Indolfi C, Dinardo G, et al. United airway disease. Acta Biomed. 2021;92(S7):e2021526.
  • Licari A, Castagnoli R, Denicolò CF, et al. The nose and the lung: united airway disease? Front Pediatr. 2017;5:44.
  • Licari A, Brambilla I, De Filippo M, et al. The role of upper airway pathology as a co-morbidity in severe asthma. Expert Rev Respir Med. 2017;11(11):855–865.
  • Gon Y, Hashimoto S. Role of airway epithelial barrier dysfunction in pathogenesis of asthma. Allergol Int. 2018;67(1):12–17.
  • Bonner K, Roberts G. Does allergy explain why some children have severe asthma? Clin Exp Allergy. 2018;48(12):1594–1605.
  • Marseglia GL, Cirillo I, Vizzaccaro A, et al. Role of forced expiratory flow at 25-75% as an early marker of small airways impairment in subjects with allergic rhinitis. Allergy Asthma Proc. 2007;28(1):74–78.
  • Tosca MA, Del Barba P, Licari A, et al. The measurement of asthma and allergic rhinitis control in children and adolescents. Children (Basel). 2020;7(5):43.
  • Ahmed H, Turner S. Severe asthma in children-a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol. 2019;54(6):778–787.
  • Arshad SH. Does allergen immunotherapy for allergic rhinitis prevent asthma? Ann Allergy Asthma Immunol. 2022;S1081-1206:00392–1.
  • Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–948.
  • Zielen S, Devillier P, Heinrich J, et al. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: a retrospective, real-world database analysis. Allergy. 2018;73(1):165–177.
  • Licari A, Manti S, Castagnoli R, et al. Targeted therapy for severe asthma in children and adolescents: current and future perspectives. Paediatr Drugs. 2019;21(4):215–237.
  • Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58(1):1–464.
  • De Filippo M, Votto M, Licari A, et al. Novel therapeutic approaches targeting endotypes of severe airway disease. Expert Rev Respir Med. 2021;15(10):1303–1316.
  • Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(1449–56.e4):1449–1456.e4.
  • Wu D, Bleier BS, Li L, et al. Clinical phenotypes of nasal polyps and comorbid asthma based on cluster analysis of disease history. J Allergy Clin Immunol Pract. 2018;6(1297–1305.e1):1297–1305.e1.
  • Licari A, Caimmi S, Bosa L, et al. Rhinosinusitis and asthma: a very long engagement. Int J Immunopathol Pharmacol. 2014;27(4):499–508.
  • Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc. 2004;1(3):264–268.
  • Tan BK, Chandra RK, Pollak J, et al. Incidence and associated premorbid diagnoses of patients with chronic rhinosinusitis. J Allergy Clin Immunol. 2013;131(5):1350–1360.
  • Lee TJ, Fu CH, Wang CH, et al. Impact of chronic rhinosinusitis on severe asthma patients. PLoS One. 2017;12(2):e0171047.
  • Ho J, Bailey M, Zaunders J, et al. Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clin Exp Allergy. 2015;45(2):394–403.
  • Matucci A, Bormioli S, Nencini F, et al. Asthma and chronic rhinosinusitis: how similar are they in pathogenesis and treatment responses? Int J Mol Sci. 2021;22(7):3340.
  • Agache I, Eguiluz-Gracia I, Cojanu C, et al. Advances and highlights in asthma in 2021. Allergy. 2021;76(11):3390–3407.
  • Head K, Chong LY, Hopkins C, et al. Short-course oral steroids as an adjunct therapy for chronic rhinosinusitis. Cochrane Database Syst Rev. 2016;4:CD011992.
  • Hopkins C, Rimmer J, Lund VJ. Does time to endoscopic sinus surgery impact outcomes in chronic rhinosinusitis? Prospective findings from the national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis. Rhinology. 2015;53(1):10–17.
  • Ho J, Hamizan AW, Alvarado R, et al. Systemic predictors of eosinophilic chronic rhinosinusitis. Am J Rhinol Allergy. 2018;32(4):252–257.
  • Tsetsos N, Goudakos JK, Daskalakis D, et al. Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review. Rhinology. 2018;6(1):11–21.
  • Agache I, Song Y, Alonso-Coello P, et al. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: a systematic review for the EAACI guidelines. Allergy. 2021;76(8):2337–2353.
  • Bachert C, Desrosiers MY, Hellings PW, et al. The role of biologics in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2021;9(3):1099–1106.
  • Sedaghat AR, Phillips KM. Keeping our eyes on the prize: personalized and precision medicine with biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol Pract. 2022;10(7):1887–1888.
  • Kowalski ML, Agache I, Bavbek S, et al. Diagnosis and management of NSAID -Exacerbated Respiratory Disease (N- ERD)—a EAACI position paper. Allergy. 2019;74(1):28–39.
  • Cho KS, Soudry E, Psaltis AJ, et al. Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease. Otolaryngol Head Neck Surg. 2014;151(4):575–581.
  • Trivedi M, ElMallah M, Bailey E, et al. Pediatric obstructive sleep apnea and asthma: clinical implications. Pediatr Ann. 2017;46(9):e332–e335.
  • Ragnoli B, Pochetti P, Raie A, et al. Interrelationship between obstructive sleep apnea syndrome and severe asthma: from endo-phenotype to clinical aspects. Front Med (Lausanne). 2021;8:640636.
  • Ha EK, Park JH, Lee SJ, et al. Shared and unique individual risk factors and clinical biomarkers in children with allergic rhinitis and obstructive sleep apnea syndrome. Clin Respir J. 2020;14:250–259.
  • Vicente E, Marin JM, Carrizo SJ, et al. Upper airway and systemic inflammation in obstructive sleep apnoea. Eur Respir J. 2016;48(4):1108–1117.
  • Alkhalil M, Schulman E, Getsy J. Obstructive sleep apnea syndrome and asthma: what are the links? J Clin Sleep Med. 2009;5(1):71–78.
  • Zheng M, Wang X, Zhang L. Association between allergic and nonallergic rhinitis and obstructive sleep apnea. Curr Opin Allergy Clin Immunol. 2018;18(1):16–25.
  • Chervin RD, Hedger K, Dillon JE, et al. Pediatric sleep questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems. Sleep Med. 2000;1(1):21–32.
  • Chung F, Abdullah HR, Liao P. STOP-bang questionnaire: a practical approach to screen for obstructive sleep apnea. Chest. 2016;149(3):631–638.
  • Ehsan Z, Kercsmar CM, Collins J, et al. Validation of the pediatric sleep questionnaire in children with asthma. Pediatr Pulmonol. 2017;52(3):382–389.
  • Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. 2010;181(4):315–323.
  • Connett GJ, Thomas M. Dysfunctional breathing in children and adults with asthma. Front Pediatr. 2018;6:406.
  • Lee JH, An J, Won HK, et al. Prevalence and impact of comorbid laryngeal dysfunction in asthma: a systematic review and meta-analysis. J Allergy Clin Immunol. 2020;145(4):1165–1173.
  • Powell DM, Karanfilov BI, Beechler KB, et al. Paradoxical vocal cord dysfunction in juveniles. Arch Otolaryngol Head Neck Surg. 2000;126(1):29–34.
  • Seear M, Wensley D, West N. How accurate is the diagnosis of exercise induced asthma among Vancouver schoolchildren? Arch Dis Child. 2005;90(9):898–902.
  • Hull JH, Backer V, Gibson PG, et al. Laryngeal Dysfunction: assessment and management for the clinician. Am J Respir Crit Care Med. 2016;194(9):1062–1072.
  • Cook J, Beresford F, Fainardi V, et al. Managing the pediatric patient with refractory asthma: a multidisciplinary approach. J Asthma Allergy. 2017;10:123–130.
  • Hew M, Denton E. Prioritizing treatable traits in airways disease. J Allergy Clin Immunol Pract. 2021;9(3):1265–1266.
  • Shieh A, Siddaiah R. Case 3: persistent respiratory distress in a teenager treated for severe asthma exacerbation. Pediatr Rev. 2018;39(5):261.
  • Traister RS, Fajt ML, Landsittel D, et al. A novel scoring system to distinguish vocal cord dysfunction from asthma. J Allergy Clin Immunol Pract. 2014;2(1):65–69.
  • Fowler SJ, Thurston A, Chesworth B, et al. The VCDQ–a Questionnaire for symptom monitoring in vocal cord dysfunction. Clin Exp Allergy. 2015;45(9):1406–1411.
  • Parsons JP, Benninger C, Hawley MP, et al. Vocal cord dysfunction: beyond severe asthma. Respir Med. 2010;104(4):504–509.
  • Baxter M, Uddin N, Raghav S, et al. Abnormal vocal cord movement treated with botulinum toxin in patients with asthma resistant to optimised management. Respirology. 2014;19(4):531–537.
  • Thomas M, McKinley RK, Freeman E, et al. Prevalence of dysfunctional breathing in patients treated for asthma in primary care: cross sectional survey. BMJ. 2001;322:1098–1100.
  • D’Alba I, Carloni I, Ferrante AL, et al. Hyperventilation syndrome in adolescents with and without asthma. Pediatr Pulmonol. 2015;50(12):1184–1190.
  • Boulding R, Stacey R, Niven R, et al. Dysfunctional breathing: a review of the literature and proposal for classification. Eur Respir Rev. 2016;25:287–294.
  • Courtney R, van Dixhoorn J, Greenwood KM, et al. Medically unexplained dyspnea: partly moderated by dysfunctional (thoracic dominant) breathing pattern. J Asthma. 2011;48(3):259–265.
  • Sedeh FB, Von Bülow A, Backer V, et al. The impact of dysfunctional breathing on the level of asthma control in difficult asthma. Respir Med. 2020;163:105894.
  • Barker N, Smith L, De Boer W, et al. Structured light plethysmography as an assessment tool for dysfunctional breathing in children. Eur Respir J. 2014;44:4318.
  • Singh M, Paul N, Singh S, et al. Asthma and Fungus: role in Allergic Bronchopulmonary Aspergillosis (ABPA) and other conditions. Indian J Pediatr. 2018;85(10):899–904.
  • Vicencio AG, Santiago MT, Tsirilakis K, et al. Fungal sensitization in childhood persistent asthma is associated with disease severity. Pediatr Pulmonol. 2014;49(1):8–14.
  • Bush A. Kids, Difficult Asthma and Fungus. J Fungi (Basel). 2020;6(2):55.
  • Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. J Allergy Clin Immunol. 2012;129(2):280–291.
  • O’Driscoll BR, Powell G, Chew F, et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy. 2009;39(11):1677–1683.
  • Jat KR, Vaidya PC, Mathew JL, et al. Childhood allergic bronchopulmonary aspergillosis. Lung India. 2018;35(6):499–507.
  • Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43(8):850–873.
  • Asano K, Hebisawa A, Ishiguro T, et al. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol. 2021;147(4):1261–1268.e5.
  • Godwin MS, Reeder KM, Garth JM, et al. IL-1RA regulates immunopathogenesis during fungal-associated allergic airway inflammation. JCI Insight. 2019;4(21):e129055.
  • Skowronski E, Fitzgerald DA. Life-threatening allergic bronchopulmonary aspergillosis in a well child with cystic fibrosis. Med J Aust. 2005;182(9):482–483.
  • Voskamp AL, Gillman A, Symons K, et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2015;3(2):192–199.
  • Parisi GF, Portale A, Papale M, et al. Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: case reports and literature review. J Allergy Clin Immunol Pract. 2019;7(5):1636–1638.
  • Castanhinha S, Sherburn R, Walker S, et al. Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. J Allergy Clin Immunol. 2015;136(2):312–322.e7.
  • Crimi C, Ferri S, Campisi R, et al. The link between asthma and bronchiectasis: state of the art. Respiration. 2020;99(6):463–476.
  • Lo D, Maniyar A, Gupta S, et al. High prevalence of bronchiectasis on chest CT in a selected cohort of children with severe Asthma. BMC Pulm Med. 2019;19(1):136.
  • Bendien SA, van Loon-Kooij S, Kramer G, et al. Bronchiectasis in severe asthma: does it make a difference? Respiration. 2020;1–9. doi: 10.1159/000511459
  • Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol. 2013;55(1):27–34.
  • Padilla-Galo A, Olveira C, Fernández de Rota-Garcia L, et al. Factors associated with bronchiectasis in patients with uncontrolled asthma; the NOPES score: a study in 398 patients. Respir Res. 2018;19(1):43.
  • Radovanovic D, Santus P, Blasi F, et al. A comprehensive approach to lung function in bronchiectasis. Respir Med. 2018;145:120–129.
  • Chen FJ, Liao H, Huang XY, et al. Importance of fractional exhaled nitric oxide in diagnosis of bronchiectasis accompanied with bronchial asthma. J Thorac Dis. 2016;8(5):992–999.
  • Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668.
  • Carpagnano GE, Scioscia G, Lacedonia D, et al. Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab. J Asthma Allergy. 2019;12:83–90.
  • Clark VL, Gibson PG, Genn G, et al. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology. 2017;22:1262–1275.
  • Wesolowska-Andersen A, Seibold MA. Airway molecular endotypes of asthma: dissecting the heterogeneity. Curr Opin Allergy Clin Immunol. 2015;15(2):163.